<>
Upadacitinib, a targeted synthetic disease-modifying anti-rheumatic drug known commercially as Rinvoq and manufactured by AbbVie, has received European Commission approval for treating severe alopecia areata in adults and adolescents aged 12 and older. The expanded indication follows data from two large Phase III clinical trials, UP-AA1 and UP-AA2, which evaluated once-daily doses of 15 mg and 30 mg against a placebo across nearly 1,400 participants.
European Commission Approval Expands Rinvoq Use to Severe Alopecia Areata
The European Commission granted the marketing authorization for Rinvoq at the end of July, adding severe alopecia areata to an existing portfolio that includes rheumatoid arthritis and atopic dermatitis, as stated by AbbVie. The European Medicines Agency also reflects the updated therapeutic indication. The approval authorizes the once-daily administration of 15 mg or 30 mg tablets for patients experiencing severe forms of the autoimmune condition.
Alopecia areata affects approximately 2 percent of the global population, causing the immune system to attack hair follicles and resulting in patchy or total hair loss on the scalp and body. Dr. Roopal Thakkar, executive vice president for research and development and chief scientific officer at AbbVie, noted that the authorization provides a new clinical option for patients managing both the physical symptoms and the often-overlooked psychological burdens of the disease.
Phase III Trials Measure Hair Regrowth Across 1,399 Participants
The safety and efficacy data supporting the European approval stem from the international UP-AA1 and UP-AA2 Phase III clinical trial program led by principal investigator Arash Mostaghimi and published in August in JAMA Dermatology. The randomized, double-blind, placebo-controlled trials enrolled 1,399 participants, including 118 adolescents, all of whom had lost at least 50 percent of their scalp hair at baseline.
Researchers measured hair loss using the Severity of Alopecia Tool, a scale ranging from 0 for no hair loss to 100 for complete hair loss. The primary endpoint was achieving a SALT score of 20 or lower at week 24, indicating that at least 80 percent of the scalp was covered with hair. Participants were assigned randomly to receive either 15 mg of Upadacitinib, 30 mg of Upadacitinib, or a placebo daily for 24 weeks.
Efficacy Outcomes Contrast Treatment Doses With Placebo Results
At the 24-week mark, statistically significant hair regrowth occurred across both treatment dosages compared to the control groups. For the 15 mg daily dose of Upadacitinib, 45.2 percent of participants in UP-AA1 and 44.6 percent in UP-AA2 achieved at least 80 percent scalp hair coverage. Among those receiving the 30 mg dose, 55 percent in UP-AA1 and 54.3 percent in UP-AA2 reached the same threshold.
In contrast, only 1.5 percent of participants in UP-AA1 and 3.4 percent in UP-AA2 who received the placebo reached a SALT score of 20 or lower. Complete scalp hair regrowth, defined as a SALT score of 0, was observed in 14.1 percent (UP-AA1) and 13.1 percent (UP-AA2) of the 15 mg cohort, and in 20.3 percent (UP-AA1) and 22.5 percent (UP-AA2) of the 30 mg cohort. Placebo groups recorded complete regrowth rates of 0 and 0.7 percent, respectively. Beyond the scalp, secondary endpoints showed that some participants experienced regrowth of eyebrows and eyelashes alongside improvements in disease-related quality of life.
JAK Inhibitors Target Underlying Immune Pathways Differently Than Cosmetic Treatments
Upadacitinib functions as a Janus kinase inhibitor, specifically inhibiting Janus kinase 1 to block inflammatory signaling pathways that drive autoimmune follicle destruction. This pharmacological mechanism separates systemic immunotherapies from conventional treatments or over-the-counter products marketed for general hair thinning. Because JAK inhibitors alter systemic immune responses, they require careful medical supervision regarding safety profiles rather than serving as lifestyle products.
Clinical trial safety data identified common adverse events including acne, upper respiratory tract infections, nasopharyngitis, and elevated creatine phosphokinase levels. Serious adverse events occurred in 1.6 percent of patients taking the 15 mg dose, 2.3 percent of those on the 30 mg dose, and 0.4 percent of the placebo group, with researchers identifying no new safety signals during the 24-week study window.
Long-Term Efficacy and Safety Remain Open Questions for Clinicians
While the 24-week trials established short-term efficacy, several clinical variables remain unaddressed. The published data apply exclusively to the initial placebocontrolled phase, leaving long-term durability and safety profiles to be established by ongoing evaluations. The trial designs excluded children under the age of 12 and individuals whose current disease episode had lasted longer than eight years, and the research did not include a direct head-to-head comparison against other approved therapies for alopecia areata.
Related reading